Garware Fulflex Doubles Revenue with Texas Medical Plant Acquisition

Automation is the key mechanism. The Jacksonville plant runs advanced injection molding, blow molding, and thermoforming lines. That cuts labor costs per unit and improves consistency – critical for medical devices that must pass FDA audits. A US-based facility also shortens shipping times and avoids import tariffs, which have become a bigger factor since the pandemic reshaped supply chains.

Doubling revenue is an ambitious target. The company needs to integrate the 250 new employees without disrupting output. The facility's existing customer contracts must be maintained or expanded. If the automation runs at high utilization and the company retains the workforce, the $200 million target is plausible. A slip in quality, a regulatory setback, or a loss of key accounts would weaken the case.

Garware Fulflex specializes in medical products, engineered polymer solutions, rehabilitation gear, and personal protective equipment. The Jacksonville acquisition moves it from a predominantly Indian-based manufacturer to a more geographically balanced one. For a trader watching the healthcare supply chain, the metrics to track are revenue growth, capacity utilization, and any regulatory filings tied to the new plant.

The company now operates 14 locations worldwide, including four US manufacturing plants.